Lauri Neyer

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

Xavier Montalban, James Sheridan, X. Montalban, 2010, The Lancet Neurology.